Abstract The prevalence of risk factors contributing to metabolic syndrome (MetS) is increasing, and numerous components of MetS are associated with increased primary breast cancer (BC) risk. However, less is known about the relationship of MetS to BC outcomes. The aim of this study was to evaluate whether MetS, characterized by increased weight, hypertension, low HDL-cholesterol, high triglycerides, and diabetes or impaired glucose tolerance, is associated with risk of second breast cancer events (SBCE) and BC-specific mortality. Retrospective cohort study of women diagnosed with incident early-stage (I-II) BC between 1990 and 2008, enrolled in an integrated health plan. Outcomes of interest were SBCE, defined as recurrence or second primary BC, and BC-specific mortality. We used multivariable Cox proportional hazards models to estimate adjusted hazard ratios (HR) and 95 % confidence intervals (CI) for timevarying exposure to MetS components while accounting for potential confounders and competing risks. Among 4,216 women in the cohort, 26 % had C3 MetS components and 13 % developed SBCE during median follow-up of 6.3 years. Compared to women with no MetS components, presence of MetS (C3 components) was associated with increased risk of SBCE (HR = 1.50, 95 % CI 1.08-2.07) and BC-specific mortality (HR = 1.65, 95 % CI 1.02-2.69). Of the individual components, only increased weight was associated with increased risk of SBCE (HR = 1.26, 95 % CI 1.06-1.49). MetS is associated with modestly increased risk of SBCE and BC-specific mortality. Given the growing population of BC survivors, further research in larger and more diverse populations is warranted.
Introduction
There are an estimated 2.8 million breast cancer (BC) survivors in the United States [1] , among whom those with Electronic supplementary material The online version of this article (doi:10.1007/s10549-014-3157-6) contains supplementary material, which is available to authorized users.
early-stage BC have 5-year survival rates of [90 % [2] . These women are at ongoing risk for recurrences, second primary breast tumors, and long-term sequelae related to their initial cancer and its treatment [2] . Accordingly, the recently updated American Society of Clinical Oncology guidelines on post-BC follow-up and management [3] describe a need for further evidence on subsets of patients that may benefit from BC survivorship care models, such as women with comorbid conditions [4] .
A large fraction of breast cancers arise in older women, many of whom are also burdened with comorbidities such as obesity, diabetes mellitus (DM), and cardiovascular disease (CVD) [4] . Co-occurrence of risk factors for both DM and CVD, such as abdominal obesity, high blood pressure, dyslipidemias, and hyperglycemia, describes the clinical profile of risk for metabolic syndrome (MetS) [5, 6] . The American Heart Association clinical definition of MetS is the presence of C3 of the following criteria: elevated waist circumference (C88 cm in women), elevated blood pressure (BP C 130/85 mm Hg), reduced HDL-cholesterol (HDL \ 50 mg/dl), elevated triglycerides (TG C 150 mg/dl), and elevated fasting glucose (FPG C 100 mg/dl) [5, 6] .
MetS includes several comorbidities linked to BC etiology, particularly obesity and diabetes [7, 8] , although associations with these conditions in combination remain to be further substantiated by additional research [9] . Increased visceral and intra-abdominal fat often present with MetS is rich in aromatase [10] , the converter enzyme of testosterone to estrogens that stimulate ductal cell proliferation, and is also a source of free fatty acids, antiapoptotic factors, and reduced adiponectin [11] . Hyperinsulinemia and insulin resistance are hallmarks of MetS and reduce levels of insulin-like growth factor (IGF) binding proteins and raise bioavailability of IGF-1, a growth factor and gonadotrophic factor in BC that also inhibits hepatic synthesis of sex hormone-binding globulin (SHBG) [12] [13] [14] . So, overweight, hyperinsulinemia and insulin resistance, and hormonal changes in postmenopausal women may contribute jointly to both MetS and breast carcinogenesis.
Comorbid conditions contributing to MetS, particularly DM and obesity, are not only risk factors for BC development but also appear to be risk factors for adverse outcomes after BC [15, 16] . However, results from studies on MetS and BC outcomes have been inconsistent and most studies have focused primarily on the evaluation of individual MetS components rather than the constellation of risk factors [9, [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] . The objective of this study was to evaluate MetS constituents individually and in combination in relation to risk of second breast cancer events (SBCE) (i.e., recurrence and second primary BC) and BC-specific mortality.
Methods

Study population and setting
We conducted the study using an established cohort, the commonly used medications and breast cancer outcomes (COMBO) study, within group health (GH), a nonprofit integrated delivery system that provides comprehensive health care to approximately 600,000 individuals throughout Washington State and parts of Idaho. GH is located within the reporting region of the Western Washington Cancer Surveillance System, a population-based cancer registry and member of the surveillance, epidemiology and end results (SEER) program [26, 27] .
Eligibility, selection, and data collection for women in the COMBO study at GH have been described previously and are summarized in Fig. 1 [28] [29] [30] . Briefly, the final cohort consisted of 4,216 women that were alive and recurrence-free for 120 days after completion of definitive surgery for incident BC and were (i) ages C 18 years; (ii) residing within the 13 Washington State counties covered by SEER; (iii) diagnosed with American Joint Committee on Cancer (AJCC) stage I or II BC; (iv) had no bilateral disease; and (v) continuously enrolled (\90 day lapse) in GH's integrated group practice for at least 1 year before and 1 year after incident BC diagnosis (unless they died).
Data were collected from 1 year before incident BC diagnosis through the earliest of death, disenrollment from GH, or end of study (August 2011). Data collection was through health plan administrative databases including GH's breast cancer screening recruitment and reminder (BSRR) survey on BC risk factors at the time of each mammography [31] , SEER, and medical record reviews (paper and electronic). SEER was the primary source of information for incident BC characteristics including diagnosis year, stage, lymph node status, hormone receptor status, and tumor size. GH's administrative data files include demographics, enrollment, inpatient and outpatient diagnoses and procedures, breast services and results, pharmacy dispensing, laboratory results, vital signs, and death [32] . The pharmacy database includes all medications dispensed at GH's outpatient pharmacies as well as reimbursement claims from contracting pharmacies. Pharmacy data are estimated to be 97 % complete [32] [33] [34] . Automated death data are from an ongoing link to Washington State death tapes [35] . The GH Institutional Review Board approved this study.
Exposure classification
Presence of MetS components, weight risk (proxy for elevated waist circumference) [36] , hypertension, low HDL, high triglycerides, and DM or impaired glucose tolerance, are our main exposures of interest as described in Table 1 . Exposure was further classified by number of MetS components to compare presence of 0 (reference), 1, 2, or C3 components. All exposures were time-varying and allowed unidirectional transition only (e.g., number of MetS components present can increase but not decrease over time).
Outcomes
Main outcomes of interest were SBCE, defined as first of recurrence in any regional or distant sites or second primary ductal carcinoma in situ (DCIS) or invasive cancer of the ipsilateral or contralateral breast [37] , and BC-specific mortality. Recurrence and second primary BC were determined by medical record reviews. Secondary outcomes included overall (all-cause) mortality.
Statistical analysis
We estimated hazard ratios (HR) and 95 % confidence intervals (CI) using Cox proportional hazards models to assess whether MetS components individually or in combination were associated with SBCE and BC-specific mortality while accounting for competing risks (i.e., death due to other causes) [38] . We modeled time from incident BC with left truncation at 120 days post-surgery to SBCE or death as a function of exposure to individual MetS components and number of MetS components present while adjusting for potential confounders. Individual events that comprise SBCE (i.e., recurrence and second primary BC) were modeled separately with the other outcome treated as a competing event [38] . Women were followed until first of SBCE, death, disenrollment, or end of study. Overall mortality was modeled in a similar fashion but with no competing risks.
Estimates for individual MetS components were adjusted for presence of other MetS components. Women in the cohort with zero MetS components present were the reference category for comparison to 1, 2, and C3 MetS components present. All multivariable models were adjusted for confounders selected a priori, including incident BC diagnosis year, age, stage, hormone receptor status, primary BC treatment, chemotherapy, endocrine therapy (time-varying), race, smoking status, menopausal status, and receipt of surveillance mammography [39] in prior 12 months (time-varying).
Proportional hazards assumptions were evaluated by testing the interaction between MetS components and the logarithm of follow-up time. There was no evidence suggesting violation of proportional hazards assumptions. All analyses were performed using SAS statistical software version 9.2 (SAS Institute Inc., Cary, NC).
Sensitivity analyses
Our approach included use of data elements as surrogates for direct clinical measurement of MetS components (e.g., documented diagnosis in the medical chart) [40] . Therefore, we performed sensitivity analyses to describe the patterns of missing data among the covariates used to define exposure to MetS components. We evaluated our assumptions regarding reasons for missing data by applying multiple imputation under a missing-at-random assumption which yielded results similar to our main analysis for SBCE and BC-specific mortality, suggesting our data were robust to assumptions made with respect to exposure classification. As such, we present results from the main analyses only.
Results
The majority were postmenopausal (median diagnosis age: 63 years), Caucasian, non-Hispanic, never smokers, and had some college education or more, and Charlson comorbidity score of zero (Table 2) . A majority of the incident BCs were AJCC stage I, node-negative, ERpositive/PR-positive, B2 cm in size, HER2-negative (if tested), treated with breast-conserving surgery ± radiation, not treated with chemotherapy, and treated with endocrine therapy. At baseline, 9 % of women had C3 MetS conditions present (Online Resource 1) with 26 % having C3 MetS conditions present throughout follow-up (Table 3 ). In women with C1 conditions during follow-up, the most prevalent conditions were weight risk (52 %), hypertension (68 %), and DM or impaired glucose tolerance (26 %). The majority of women with C3 MetS conditions had the following three conditions: weight risk ? hypertension ? DM or impaired glucose tolerance (67 %).
Median follow-up was 6.3 years (interquartile range, 3.7-9.7 years), which varied by diagnosis date with women diagnosed in earlier study years having longest follow-up.
Among the 4,216 eligible women, 13 % experienced SBCE (first of n = 415 recurrences and n = 143 s primary BC) (Online Resource 2). Among recurrences, 67 % were distant, 32 % local or regional, and 1 % DCIS. Among second primary BC, 21 % were DCIS, 49 % stage I, 21 % stage II, 4 % stages III or IV, and 5 % unknown stage. Compared to women with no SBCE during follow-up, women experiencing a SBCE were more likely to have been diagnosed with AJCC stage II BC, be peri-or premenopausal, lymph node positive, ER and/or PR negative, tumor size [2 cm, HER2-positive, treated by mastectomy, treated with chemotherapy, not treated with endocrine therapy, and have incident BC detected by diagnostic versus surveillance mammography. Overall, 6 % of women experienced BC-specific death and 16 % died due to other (non-BC-related) causes.
In multivariable models, we observed a dose-response relationship between number of MetS components and risk of SBCE, with risk for those with C3 MetS components significantly elevated compared to women with 0 MetS components (HR = 1.50, 95 % CI 1.08-2.07) (Fig. 2) . Weight risk (BMI C 27.7 kg/m 2 ), adjusted for other MetS conditions, was also independently associated with increased risk of SBCE (HR = 1.37, 95 % CI 1.14-1.64) (Fig. 3) . Associations with risk of recurrence were stronger for both C3 MetS conditions present (HR = 1.65, 95 % CI 1.15-2.38) and weight risk (HR = 1.49, 95 % CI 1.21-1.83). No statistically significant association was observed for second primary BC risk with C3 MetS conditions (HR = 1.16, 95 % CI 0.59-2.27) or weight risk (HR = 1.25, 95 % CI 0.88-1.77) but point estimates suggested potential increased risk. There were no significant associations between other MetS components and either SBCE or recurrence, but point estimates suggested a possible increase in risk of second primary BC associated with high triglycerides. The presence of C3 MetS components was associated with increased risk of BC-specific death (HR = 1.65, 95 % CI 1.02-2.69) compared to women with 0 MetS components (Fig. 2) . Weight risk was also associated with increased risk of BC-specific mortality (HR = 1.36, 95 % CI 1.04-1.78), whereas no other individual MetS components were significantly associated with BC-specific mortality. Compared to women with 0 MetS components, presence of one (HR = 1.17, 95 % CI 1.00-1.38), two (HR = 1.36, 95 % CI 1.12-1.65), or C3 MetS components (HR = 1.81, 95 % CI 1.44-2.29) were associated with increased risk of overall mortality (Fig. 2) . Hypertension (HR = 1.33, 95 % CI 1.13-1.55) and DM or impaired glucose tolerance (HR = 1.53, 95 % CI 1.26-1.71) were also independently associated with a higher risk of death.
Discussion
In this population-based, retrospective cohort study, presence of C3 MetS components was associated with risk of recurrence and BC-specific mortality but not second primary BC. Of individual components, only weight risk was associated with increased risk of recurrence and BC-specific mortality; hypertension and DM or impaired glucose tolerance were associated with increased risk of overall mortality; and estimates suggested a possible increased risk of second primary BC with high triglycerides.
Few studies have examined combined MetS risk factors in relation to SBCE. Our observed association between C3 MetS components and recurrence is consistent with increased risk of recurrence reported by Pasanisi et al. [41] (HR = 3.0, 95 % CI 1.2-7.1) in a dietary intervention trial including 110 postmenopausal BC patients, although we observed a more modest increase in recurrence risk. Our findings of increased risk of SBCE with weight risk in MetS concur with other studies [16, [21] [22] [23] reporting a relation between increased BMI and prognosis following BC but not others [20, 24] . In a study of 18,967 women in a population-based Danish cohort, Ewertz et al. [16] [42, 43] . Presence of DM can impact BC prognosis through the hypothesized role of insulin resistance and hyperinsulinemia in breast carcinogenesis, as well as through possible differences in treatment decisions and intensity of chemotherapy side effects and complications [44] . While our results were not statistically significant for DM, they suggest that DM but not impaired glucose tolerance may increase the risk of recurrence and second primary BC. However, results from a retrospective cohort study of 3,124 women with stages I-III BC by Kiderlen et al. [45] suggest a decreased risk of recurrence in women with diabetes compared to women without diabetes (HR = 0.77, 95 % CI 0.59-1.01), particularly in ages C75 years (HR = 0.67, 95 % CI 0.45-0.98). One possible explanation for results indicating no association or possibly an inverse relationship is that adverse influences of DM or impaired glucose tolerance on BC prognosis could be counterbalanced by potential protective effects of some DM medications, such as metformin [46] . Kiderlen et al., suggested that the majority of women with DM in their study used metformin. At GH, DM management largely includes metformin use, particularly in more recent years; throughout follow-up, 45 % of women with DM had C1 pharmacy dispensings for metformin. However, these differences in our results in the context of these commonly used medications illustrate the need for larger epidemiological studies that examine the impact of treatment and control of MetS conditions as well as randomized trials of these medications in the adjuvant treatment setting [47] to help further substantiate their potential role in BC prognosis. Evaluating medications was out of scope for this study. Studies evaluating MetS risk factors in relation to second primary BC risk are also limited. In our study, no statistically significant association was observed between number of MetS components and risk of second primary BC, although results were suggestive of an increased risk of second primary BC with weight risk and DM. The low number of second primary BC (n = 143) that occurred in this cohort limited our ability to establish such a relation and future studies with greater power are needed to confirm potential associations between MetS components and second primary BC. Some studies describe increased risk of second primary BC with increased weight [24, [48] [49] [50] [51] , but others report no association with increased BMI or obesity [52] [53] [54] . We observed a possibly increased risk of second primary BC with DM but not with impaired glucose tolerance only. In kind, a population-based case-control study [55] of women aged 40-79 years diagnosed with ERpositive, stages I-III, incident primary BC found that women with DM had an increased risk (OR = 2.2, 95 % CI 1.3-3.6) of second primary contralateral BC compared to women with no history of DM.
No other published studies have examined the role of hypertriglyceridemia (TG [ 150 mg/dl) specifically with risk of second primary BC. In our study, we observed an increased risk of second primary BC with elevated triglycerides (HR = 8.38, 95 % CI 1.04-67.69), although the estimate was unstable due to small sample sizes and should be interpreted cautiously. The role of serum triglycerides in BC is not clear, and studies examining primary BC incidence related to elevated triglycerides are inconsistent, showing no association in some prospective cohort studies [56, 57] , but a positive association in other cohort [58] and case-control studies [59, 60] . There is suggestion that lipoprotein lipase may regulate clearance of triglycerides from blood to tissue and its activity in adipose tissue decreases in cancer patients, contributing to hypertriglyceridemia [61] . While tamoxifen is associated with reduced [36] risk of second primary BC [62] , tamoxifen and estrogen also have a known role in increasing serum triglyceride levels and sometimes inducing severe hypertriglyceridemia [63] . In light of the extremely elevated risk of second primaries that we observed with high triglycerides and elevated point estimates for SBCE and recurrence, additional studies are warranted in larger populations.
Risk of overall mortality in the general population is increased with MetS, and we observed increased risk of overall mortality with increasing number of MetS components and with DM and hypertension individually. In a large cohort study of 9,677 women aged C65 years [64] , MetS defined by co-prevalence of DM, obesity, and hypertension was associated with a 2.5-fold increased risk (95 % CI 2.2-2.9) of overall mortality, as well as with presence of DM (HR = 1.7 95 % CI 1.4-1.9), obesity (HR = 1.2 95 % CI 1.1-1.4) and hypertension (HR = 1.3 95 % CI 1.2-1.4) individually. Also similar to our findings, a meta-analysis by Peairs et al. [15] reported preexisting diabetes in women with BC was associated with a 49 % increased risk (95 % CI 1.35-1.65) of all-cause mortality. Strengths of this study include the use of a well-characterized population-based cohort of BC survivors with comprehensive and high-quality data on incident BC characteristics and treatment from both a validated registry and medical charts, health care utilization including medication use details and breast services, BC outcomes, and death. Complete information on death, other cancers, and disenrollment allows the application of robust analytic methods to address potential competing risks.
Our study is not without limitations. COMBO uses data from a single health plan and an insured and primarily Caucasian population. This may limit generalizability to some populations in the U.S., such as African American and Mexican American women where prevalence of MetS is estimated to be greater than that in White women [65] . Loss to follow-up is a possible source of bias with 18 % of women in the study censored due to disenrollment from the health plan. Also, residual confounding is possible in any observational study. We ascertained and considered the majority of potential confounders but lacked information on certain modifiable lifestyle factors such as diet and physical activity. We did not include adjustment for annual Charlson comorbidity scores in our main analysis because of the contribution of MetS components to their calculation. However, in sensitivity analyses, there was little change in risk estimates for SBCE and BC-specific mortality with adjustment for time-varying Charlson scores.
Our ability to detect associations between MetS components and SBCE is also limited by low occurrence of some events (i.e., second primary BC, 3.4 %) and low prevalence of some MetS components (i.e., hypertriglyceridemia, 1.6 %). We did not have information on duration of diseases at BC diagnosis because only 1 year of enrollment prior to BC diagnosis was required. 
Conclusion
Our study examining MetS risk factors suggests that MetS is associated with a modestly increased risk of SBCE and BC-specific mortality that is concerning due to the growing population of BC survivors and prevalence of MetS risk factors. Understanding the role of MetS in relation to BC outcomes may be useful for prioritizing clinical care and management of these conditions following diagnosis and treatment of early-stage BC with potential long-term survival. These findings highlight the considerable prevalence of comorbidities contributing to MetS among BC survivors and their potential impact on cancer-related outcomes. 
